- AnaptysBio ( NASDAQ: ANAB ) said that top-line data from a phase 2 trial of imsidolimab for the chronic skin condition hidradenitis suppurativa missed its primary endpoint .
- Shares are down 16% in post-market trading.
- The drug did not show any improvement compared to placebo. Imsidolimab also missed on key secondary endpoints.
- As a result, AnaptysBio is ending development of imsidolimab in hidradenitis suppurativa, which is characterized by lumps in places such as the armpits and groin.
- AnatysBio ( ANAB ) said it will focus on its immune cell modulator pipeline, including rosnilimab and ANB032, both in phase 1 for, respectively, alopecia areata and inflammatory diseases.
- Seeking Alpha's Quant Rating views AnaptysBio ( ANAB ) as a hold with high marks for revisions and momentum .
For further details see:
AnaptysBio skin condition candidate fails mid-stage trial; shares down 16%